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1. Postpartum depression (PPD), now termed perinatal depression by the DSM-5, is a 
common medical complication associated with a poor outcome. 
2. The majority of available data on the pathophisiology of PPD have been conducted in 
recent years. Most of them deal with endocrinological and immunological 
biomarkers, while only few biochemical/genetic biomarkers have been investigated 
showing interesting results. 
3. Some robust associations with an increased risk of peripartum depressive symptoms 
have been reported with HPA axis, hormonal changes, IL-6, vitamin D, fatty acid, 
BDNF.  
4. Affective disorders in pregnant women has to be detected as soon as possible and 
treated with focused therapies in order to reduce the impact of PPD on offsprings and 





Postpartum depression, now termed perinatal depression by the DSM-5, is a clinically 
relevant disorder reaching 15% of incidence. Although it is quite frequent and associated with 
high social dysfunction, only recently its underpinning biological pathways have been explored, 
while multiple and concomitant risk factors have been identified (e.g. psychosocial stress). 
Peripartum depression usually has its onset during the third trimester of pregnancy or in the 
postpartum, being one of the most common medical complications in new mothers.  
Purpose of the present review is to summarize the state of art of biological biomarkers 
involved in the pathogenesis of perinatal depression, in view of the fact that suboptimal prenatal 
milieu can induce permanent damage in subsequent offspring life and have a negative impact on 
mother-child relationship. Furthermore, parents’ biological changes due to medical/psychiatric 
disorders or stress exposure could have an impact on offspring: a concept known as 
‘intergenerational transmission’, acting by variations into gametes and the gestational uterine 
environment.  
Given the evidence that perinatal mental disorders involve risks for the mother and 
offspring, the search for reliable biomarkers in high-risk mothers actually represents a medical 


















Perinatal depression, which includes major and minor depressive episodes, is one of the 
most common medical complications during pregnancy and postpartum (Committee on Obstetric 
Practice, 2015). As for other psychiatric disorders, perinatal depression is a complex condition, 
having a multi-dimensional phenotype and involving psychological/social factors beyond 
biological aspects (Martini et al., 2015; Di Florio and Meltzer-Brody, 2015; Weobong et al, 
2014; O’Hara and Wisner, 2014; Yim et al., 2015). The clinical symptoms associated with 
perinatal depression are commonly low mood, sadness, irritability, impaired concentration, 
feeling of guilt about the baby care and feeling overwhelmed. PPD seems to have several distinct 
phenotypes as recently reported by consortium Postpartum Depression: Action Towards Causes 
(PACT). Women in class 1 had the least severe symptoms (mean EPDS score 10·5), followed by 
those in class 2 (mean EPDS score 14·8) and those in class 3 (mean EPDS score 20·1). The most 
severe PPD symptoms were significantly associated with poor mood (mean EPDS score 20·1), 
increased anxiety, onset of symptoms during pregnancy, obstetric complications, and suicidal 
ideation. In class 2, most women (62%) reported symptom onset within 4 weeks postpartum and 
had more pregnancy complications than in other two classes (69% vs 67% in class 1 and 29% in 
class 3). The need of efficacious treatments is justified by high-risk suicidality, near to 20% of 
all postpartum deaths and reduced maternal sensitivity (Lindahl et al., 2005; Meltzer-Brody and 
Jones, 2015).  
Lifetime occurrence of perinatal mood episodes was analysed in a large sample of women 
with bipolar I disorder, bipolar II disorder and RMD and rates of perinatal episodes per 
pregnancy/postpartum period were recorded. More than two-thirds of all diagnostic groups 
reported at least 1 lifetime episode of illness during pregnancy or the postpartum period, being 
mood episodes significantly more common in the postpartum period in bipolar I disorder and 
RMD; the risk of a perinatal major affective episode per pregnancy/postpartum period was lower 
in women with RMD (Di Florio and Dowswell, 2013). Currently we know that significant risk 
factors for early postpartum depressive symptoms are a history of mental illness including past 
MDE, PMDD, mood symptoms during the third trimester and low partner support (Bloch et al., 
2006; Milgrom et al., 2008; Stuart-Parrigon and Stuart, 2014). A large prospective cohort study 
in perinatal mental health - the beyondblue National Postnatal Depression Program- conducted in 
all six states of Australia reported that antenatal depressive symptoms appear to be as common as 
postnatal depressive symptoms, thus confirming clinical reports. A very interesting study by 
Patton et al. (2015) - the Victorian Intergenerational Health Cohort Study (VIHCS) assessed the 
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extent to which women with perinatal depressive symptoms had a history of mental health 
problems before conception. They reported that perinatal depressive symptoms are mostly 
preceded by mental health problems that begin before pregnancy, in adolescence or young 
adulthood, being women with a history of persisting common mental disorders before pregnancy 
a high-risk group. In light of their study they conclude that the window for considering 
preventive intervention for perinatal depression should be extended to the time before 
conception. A recent prospective mother-child study conducted in Greece analysed the relation 
between maternal trait anxiety and depression during pregnancy and the association with PPD, 
reporting the importance of antenatal maternal mental health and well being in identifying 
women at risk for PPD (Koutra et al., 2014).  
The effects of prenatal maternal stress impact mother and foetus/child bonding and infant 
growth in utero, furthermore, prolonged stress may result in hyperactivity of the stress system, 
altering glucocorticoid feedback, creating a vulnerability to addictive and mood disorders in 
offsprings (Brittain et al., 2015). In the light of significant personal and social burden of PPD, 
purpose of the present review is to evaluate the state of art of the available biological biomarkers 
that could be useful in early detection of perinatal depression. 
 
2. Methods 
   
In order to provide an update overview, a research in main databases (Pubmed, ISIWEB 
of Knowledge, PsycINFO) was performed. Suitable articles were sourced from a comprehensive 
literature search and from references identified through other studies. All articles, concerning 
major/minor depression in pregnancy and post-partum were included. Keyword were 
“depression” matched with “pregnancy”, “post partum”, “perinatal” “biomarkers”, 
“biochemistry”, “immunology” “endocrinology”, “genetic”, “epigenetic”, “clinical trials”. 
Exclusion criteria were: animal studies, studies with different diagnosis (e.g. bipolar disorder), 
physiological studies, studies assessing rating scales, studies assessing the impact of pathological 
pregnancy on offsprings, neuroimaging studies.  
 The review covers findings from 1969 to 2015, last search was conducted on November 
2015, even though most of articles have been produced in the last 10 years.  After applying the 
inclusion and exclusion criteria, a total of 127 papers were included in the review, the majority of 
data being represented by endocrinological and immunological studies, while less studies have 
analysed biochemical and genetic pathways. 
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3. Genetic studies 
As for other psychiatric disorders, PPD is, at least, partially genetic determined. The gene 
encoding BDNF is a strong candidate for PPD pathogenesis: its polymorphism (Val66Met) alters 
the regulated protein secretion (the Methionine variant is associated with insufficient secretion 
compared to the Valine variant). A study by Figueira et al. (2010) evaluated BDNF gene 
Val66Met polymorphism and the association with PPD, however no difference in BDNF 
genotype distribution was observed between the depressed and non-depressed women. A case-
control study evaluated whether functional polymorphic variants, BDNF Val66Met, 5-HTTLPR, 
or Period2 (PER2) SNP 10870, are associated with PPD symptoms without revealing any 
statistically significant association between such polymorphisms and PPD symptoms. 
Interestingly, a significant association between BDNF Met66 carrier status and development of 
PPD symptoms was found at 6 weeks postpartum among mothers delivering during 
autumn/winter (Comasco et al., 2011). A case-control study found a distinctive gene expression 
signature of mononuclear cells after delivery in mothers with an emergent PPD with respect to 
healthy mothers, bringing initial evidence that early cell mapping may harbor valuable 
prognostic information to identify PPD onset (Segman et al., 2010; Licinio, 2010). SNPs in 
FADS1/FADS2, encoding Delta-5 and Delta-6 desaturase, rate-limiting enzymes in metabolism 
of LA to ARA and alpha-linolenic to eicosapentaenoic and DHA have been associated with 
higher PPD risk (Xie and Innis, 2009). 
A genome-wide association study found that women with PPD displayed an increased 
sensitivity to estrogen signaling, confirming the previously proposed hypothesis of increased 
sex-steroid sensitivity as a susceptibility factor for PPD (Mehta et al., 2014). Nine 
polymorphisms in estrogen receptor alpha gene (ESR1) were studied in postpartum women 
supporting a role for ESR1 in the etiology of PPD, possibly through the modulation of serotonin 
signaling (Pinsonneault et al., 2013). Recently, Pařízek et al. (2014) found that androgen levels 
correlated with postpartum mood disorders. A prospective study by Kaminsky and Payne (2014) 
identified estrogen mediated epigenetic changes associated with PPD, identifying two 
biomarkers, HP1BP3 and TTC9B, which predicted PPD in a sample of high risk women. In 
addition, the authors found a decrease in the ratio of monocytes to lymphocytes plus 
granulocytes in the antenatally depressed women in relation with HP1BP3 methylation status, 
thus supporting the hypothesis of a higher sensitivity to estrogens in women at risk for PPD. A 
cross-species translational study evaluating DNA methylation, confirmed the link of the two 
biomarker loci, HP1BP3 and TTC9B, with PPD onset with an area under the curve (AUC) of 
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0.87 in antenatally euthymic women and 0.12 in a replication sample of antenatally depressed 
women, thus supporting the involvement of altered sensitivity to estrogen-mediated epigenetic 
alterations in PPD etiology (Guintivano et al., 2014). Recently Osborne and colleagues (2015) 
replicated Kaminsky/Guintivano findings (2014), in particular TTC9B and HP1BP3 DNA 
methylation have been associated with estradiol and allopregnanolone levels over the course of 
pregnancy, suggesting that epigenetic variation at these loci may be important for mediating 
hormonal sensitivity and possibly predicting PPD onset.  
Maternal RNA was collected in order to analyse the pheripheral expression of 
glucorticoid receptor (GR) co-chaperone genes in women with a lifetime history of mood or 
anxiety disorder. This study reported that prenatal depressive symptoms appear to be associated 
with altered regulation of GR sensitivity, possibly being a biomarker for depressive symptoms 
during pregnancy (Katz et al., 2012). A prospective study found that PPD risk correlated 
significantly with 17β-estradiol (E2) induced DNA methylation change, suggesting an enhanced 
sensitivity to estrogen-based DNA methylation reprogramming in women at risk for PPD 
(Guintivano et al., 2014). A prospective study investigated the association of genetic variants in 
the glucocorticoid receptor (GR, NR3C1) and corticotropin releasing hormone receptor 1 
(CRHR1) genes with increased risk for PPD, reporting a positive association in specific SNPs of 
genes, involved in 'stress' responses, that might contribute in the genetics of high-risk for 
depression during pregnancy and postpartum (Engineer et al., 2013). A case-control, prospective 
study analyzed steroid hormone function (NR3C1, FKBP5, ESR1, ESR2, PGR, AR, AKR1C2), 
neurotransmitter function (SLC6A4, MAOA, COMT, HTR2A), and neurotrophin function 
(BDNF), finding an association of three single nucleotide polymorphisms in the serotonin 2A 
receptor (HTR2A) with PPD (El-Ibiary and Cocohoba, 2008). A case-control study of oxytocin 
receptor gene (OXTR) DNA methylation (CpG site -934) and genotype (rs53576 and rs2254298) 
were assayed from DNA extracted during pregnancy: an interaction was found between rs53576 
and methylation in the OXTR gene amongst women who did not have depression prenatally but 
developed PPD. Those women with GG genotype showed 2.63 greater odds of PPD for every 
10% increase in methylation level, whereas methylation was unrelated to PPD amongst "A" 
carriers; OXTR could be a susceptible genotype play a contributory role in the etiology of PPD 
(Bell et al., 2015). 
A prospective pregnancy cohort study examined associations between maternal 
depressive symptoms and placental expression of genes involved in glucocorticoid and serotonin 
transfer, reporting that altered placental function as a potential gestational-age-specific marker of 
PPD risk (Reynolds et al., 2015). A cohort study evaluated single nucleotide polymorphisms 
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(SNPs) of tryptophan hydroxylase 2 (TPH2) gene in pregnant and postpartum women. The 
haplotype block in the promoter region of TPH2 showed significant associations with depression 
both in pregnancy and postpartum. Furthermore, a haplotype block in intron 8, had an influence 
on depression scores during pregnancy, but not after birth; the effect of TPH2 haplotypes on 
EPDS values was strongest during pregnancy and 6 months after birth (Fasching et al., 2012). 
Previously, Lin et al. (2009) investigated the role of TPH2 in the etiology of peripartum major 
depression and anxiety disorders, finding that TPH2 2755A allele increased 1.73  times the risk 
of peripartum major depression and anxiety disorders.  
The serotonin-transporter linked polymorphic region (5-HTTLPR) S-allele carrier status 
was found to predict late postpartum depressive symptom severity only in case of negative life 
events (Mehta et al., 2012). An at-risk population sample was genotyped for 5-HTTLPR, 
reporting that the S-allele carrier status predicted the occurrence of a MDE in the early post-
partum period (Binder et al., 2010). Previously, MAOA, COMT and 5-HTT polymorphisms 
were analysed, finding a significant interaction between these polymorphisms and the 
development of depressive symptoms in pregnancy; particularly, women carrying the 
combination of low activity variants of MAOA and COMT showed increased EPDS scores at the 
end of pregnancy and postpartum, but not during early pregnancy or 12-week postpartum 
(Doornbos et al., 2009a). A recent Chinese study reported the association between 5-HTTLPR  
allele LL and major depressive disorder in postpartum women (Zhang et al., 2014).  Finally, an 
association between the COMT AA genotype (Met/Met) and PPD was reported by Alvim-Soares 
et al. (2013). 
For a summary of the reviewed studied observing changes in genetic/epigenetic pathways 




4. Biochemical studies 
 Depressive symptoms and serum zinc/magnesium levels were determined in antepartum 
and postpartum, revealing a relationship between severity of depressive symptoms and decreased 
serum zinc (but not magnesium) concentration in PPD (Wójcik et al., 2006). No relationship 
between maternal iron status and PPD was reported in a Chinese sample (Armony-Sivan et al., 
2012). A prospective cohort study reported no significant associations between major depressive 
disorder (MDD) and nutritional biomarkers in mid-pregnancy (Bodnar et al., 2012). A recent 
cross-sectional Japanese study suggests that a higher intake of yogurt and calcium may be 
associated with a lower prevalence of depressive symptoms during pregnancy (Miyake et al., 
2015b). 
 It is known that vitamin D has regulatory functions in immune system, furthermore it has 
been suggested that vitamin D could act as a potential neurosteroid: the relationship between this 
vitamin and depressive symptoms has been explored in these years with inconsistent results. In 
2010 Murphy et al. postulated that there may be a negative correlation between vitamin D levels 
and PPD, being women with lower vitamin D levels at higher risk of depression. A significant 
negative correlation between vitamin D levels in the first trimester of pregnancy and depressive 
symptoms in the second trimester was later reported in two different studies (Cassidy-Bushrow 
et al. 2012a; Brandenbarg et al. 2012). Data by Gur and collegaues (2014) pointed out that lower 
maternal 25-hydroxy vitamin D3 levels, measured in a large prospective cohort study during the 
second trimester of pregnancy, were associated with higher levels of PPD at all time points (1st 
week, 6
th
 week, 6 months) (p=0.003, p=0.004 and p<0.001, respectively): data confirmed in a 
prospective cohort study by Robinson et al. (2014), reporting a significant correlation between 
vitamin D levels in pregnancy and PPD. A cross-sectional study, by Miyake et al. (2015a), found 
that higher dietary vitamin D intake was significantly associated with a lower prevalence of 
depressive symptoms during pregnancy. A recent prospective study reported among women with 
higher levels of inflammatory markers, an association between lower prenatal log 25(OH) D and 
significantly higher PPD symptoms (Accortt et al., 2015). 
A prospective cohort study evaluated the association between serum lipids and depressive 
symptom scores during pregnancy: HDL-c concentrations were inversely associated with 
changes in EPDS score (Teofilo et al., 2014). Long-chain polyunsaturated fatty acids (LC-
PUFA), particularly DHA and AA, were found to have an important role in foetal and infant 
growth and development. Observational studies have suggested an association between low 
DHA status after pregnancy and PPD. A study by Otto et al. (2003), compared DHA contents in 
plasma at delivery and after 32 weeks and evaluated mood symptoms in relation to EPDS, 
 11 
reporting a lower availability of DHA in the postpartum period in women included in the 
“possible depressed” group. Since LC-PUFA required by the foetus is supplied by preferential 
placental transfer of preformed LC-PUFA rather than their precursor, it has been hypothesized 
that additional LC-PUFA maternal supply, especially DHA, during pregnancy may improve 
maternal and infant outcomes. Currently, there are not sufficient data proving that the 
consumption of enriched n-3 LC-PUFA oils during pregnancy reduces the risk for PPD (De 
Giuseppe et al., 2014). Lower plasma DHA concentration was significantly associated with 
prenatal depressive symptoms in a Japanese sample, however low dietary fatty acid intake was 
not associated with depressive symptoms (Shiraishi et al., 2015). DHA supplementation, 
perceived stress and higher cortisol rate in response to a stressor during pregnancy were studied 
in a sample of African American women: DHA supplemented group reported lower levels of 
perceived stress at 30 weeks of gestation, lower cortisol output and a more modulated reaction in 
response to stress (Keenan et al., 2014). PUFA status in late pregnancy was studied in a large 
sample of women only a slightly link between fatty acids status in late pregnancy and PPD risk 
was reported (Parker et al., 2015). A low omega-3 index in late pregnancy was associated with 
higher depression score three months after delivery in a community-based prospective cohort 
(Markhus et al., 2013). A study by Sallis et al. (2014) found a weak positive association between 
omega-3 FAs and PPD.  Supplementation of low doses of DHA or DHA plus AA during 
pregnancy would not prevent PPD symptoms (Doornbos et al., 2009b). EPA-rich fish oil and 
DHA-rich fish oil supplementation did not prevent depressive symptoms during pregnancy or 
postpartum in a sample of pregnant women at risk for depression (Mozurkewich et al., 2013). A 
prospective cohort study evaluated the prevalence of suicide risk (SR) and MDE in early 
pregnancy, as well as the relationship of serum fatty acid status: it reported that women with 
higher serum AA and AdA levels had a greater likelihood of SR and MDE (Vaz et al., 2014). 
The mother-offspring cohort study “Growing Up in Singapore Toward healthy Outcomes” 
(GUSTO) evaluated plasma LC-PUFA status during pregnancy and perinatal period, finding that 
lower plasma total omega-3 PUFA concentrations and higher plasma omega-6 were associated 
with increased antenatal anxiety but not postpartum anxiety: in addition, no association between 
plasma PUFAs and PPD was found (Chong et al., 2015). Previously, the same group examined 
the relationships of plasma folate and vitamin B12 concentrations with perinatal depression in a 
sample of pregnant women: plasma folate concentrations were significantly lower in women 
with probable antenatal depression, whereas, no difference in folate concentrations was observed 
in those with and without probable PPD (Chong et al., 2014). A cross-sectional study, conducted 
in a sample of urban South Indian pregnant women, reported that blood concentrations of 
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vitamin B12 and folate were not associated with depressive symptoms (Lukose et al., 2014). 
Omura et al. (2002) compared plasma biopterin, a co-factor involved in the fenilananine and 
triptofan metabolism, in pregnancy and early puerperal period with respect to a control group. 
They reported a correlation between Zung's depressive scores and the total biopterin levels; the 
authors hypothesed that a depressive state in pregnancy or in the early puerperal period could 
have the same neurochemical basis as in normal depression. Lewis et al. (2012) reported no 
strong evidence that folic acid supplementation reduces the risk 
of depression during pregnancy and up to 8 months after pregnancy. A Chinese study found 
significantly higher homocysteine level in women with PPD than that in the control 
group (Huang et al., 2015). 
BDNF levels play a critical role in the pathophysiology of depression. A German study 
analysed maternal BDNF serum levels reporting a marked decrease both of serotonin (5-HT) and 
BDNF levels and significantly higher cortisol levels in case of maternal depression, thus, 
women, displaying marked decrease of BDNF serum levels before and after childbirth, could 
have an increased risk for PPD (Lommatzsch et al., 2006). Some years later, BDNF levels were 
quantified in women with three or more stressful life events and they were found to have lower 
BDNF levels; furthermore, serum BDNF levels in women with PPD and presenting suicide risk 
were significantly lower with respect to women without suicide risk (Pinheiro et al., 2010). In a 
recent study by Fung et al (2015) lower maternal serum BDNF levels in early pregnancy have 
been associated with antepartum depression.  
For a summary of the reviewed studied observing changes in biochemical pathways in 
perinatal depression see Table 2. 
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5. Immunological studies 
 
Immune system may contribute to PPD onset, according to psychoneuroimmunology 
model, originally suggested by Chrousos in 1995 and recently expanded (Elenkov et al., 2005; 
Corwin et al., 2010; Ellsworth-Bowers and Corwin, 2012). Currently we know that prolonged or 
excessive proinflammatory immune system activation (IL-1, IL-6, and TNF-α) is one of the 
mechanisms involved in depression (Altamura et al., 2014: Raison et al., 2006; Schiepers et al., 
2005), even in perinatal episodes (Osborne and Monk, 2013). In addition postpartum depressive 
episodes share etiological similarities with immune-related disorders. A very interesting cohort 
study, carried out through the Danish population registry, confirmed the association between pre-
eclampsia and postpartum psychiatric episodes; primiparous women had a higher risk of first-
onset psychiatric episodes during the first month postpartum when pre-eclampsia was diagnosed 
during pregnancy. Furthermore, having both pre-eclampsia and a somatic co-morbidity resulted 
in the highest risk of psychiatric episodes during the 3-month period after childbirth (Bergink et 
al., 2015). Similar data about primiparous women were reported in a retrospective study by Di 
Florio et al. (2014). It is known that ischemic placenta releases factors that provoke a generalized 
maternal endothelial dysfunction, being inflammatory cytokines (IL6, TNF α and CRP) elevated 
in severe preeclampsia (Udenze et al., 2015; Lambert et al., 2014).  
Interestingly, the administration of atypical antipsychotics in animal models, such as 
clozapine, seems to prevent the neuropathological alterations induced by maternal immune 
activation during pregnancy (Piontkewitz et al., 2009, 2011). TNF-α and IL-6 were quantified in 
the postpartum: a positive association between cytokine levels and depressive mood was 
reported in a study by Boufidou et al. (2009). A study, examining the relationships among stress, 
fatigue, depression, and cytokines was carried on in late pregnant women and at 4-6 postpartum 
weeks. In this study, mothers experienced more depressive symptoms prenatally than 
postnatally; furthermore all analysed cytokines did not show significant change from late 
pregnancy to postpartum with the exception of Granulocyte Colony-Stimulating Factor (G-CSF), 
an anti-inflammatory cytokine, that resulted to be increased. Interestingly, only stress was related 
to macrophage inflammatory protein-1β (MIP-1β), a chemokine that has the ability to induce 
chemotaxis and that plays an important role in embryo implantation and labor (Cheng and 
Pickler, 2014). Depression and inflammation are associated with poorer birth outcomes: a study 
with African-American women reported higher levels of some inflammatory biomarkers (IL-6, 
IL-1), were directly associated with more depressive symptoms and a disparate burden of poorer 
birth outcomes (Cassidy-Bushrow et al., 2012b). Similar results were reported by Azar and 
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Mercer (2013): early and midgestation women with mild to moderate prenatal depressive 
symptoms were found to have increased inflammatory markers, in particular IL-6 levels. A 
prospective study found an early increase of IL-1beta after delivery in depressed women with 
respect to healthy ones, suggesting that elevated IL-1beta early in the postpartum may increase 
the risk of PPD (Corwin et al., 2008). 
Studies in humans and animals link maternal infection and imbalanced levels of 
inflammatory mediators with a lifetime increased risk for neuropsychiatric disorders. In 
particular, exposure to viral or bacterial agents is critical if happens during the second trimester 
of human gestation (Ashdown et al., 2006). Pregnant women were studied after receiving 
influenza virus vaccination and depressive symptoms were associated with sensitization to 
inflammatory response during pregnancy, thus women with greater depressive symptoms may be 
more vulnerable to negative sequelae of infectious illness during pregnancy (Christian et al., 
2010). Previously, the same group (2009), reported that patients with higher depressive scores 
had higher levels of IL-6 and marginally higher TNF-alpha. In mothers with PPD, regulatory T 
cells were significantly increased both during pregnancy and postpartum, and their number 
predicted future development of PPD. Furthermore, after delivery the decrease of CXCR 1, a 
chemokine receptor expressed on the surface of neutrophils in mammals, was significantly 
higher in depressed mothers also having elevated neopterin levels, which are a biomarker of 
inflammation (Krause et al., 2014). Plasma pro- and anti-inflammatory cytokines were measured 
in pregnant and postpartum women, reporting higher cortisol in depressed women. Furthermore, 
a family history of depression, high cortisol levels and higher pro-inflammatory state as shown 
by IL8/IL10 ratio were all significant predictors of subsequent PPD symptoms. In particular, one 
unit increase each in the IL8/IL10 ratio and cortisol resulted respectively in 1.50 and 2.16 fold 
increased risk of PPD (Corwin et al., 2015). 
Cord/maternal blood IgG ratio was decreased in depressed women compared to controls; 
thus major depression during pregnancy could reduce prenatal transfer of IgG from mother to 
neonate (Kianbakht et al., 2013).  
A longitudinal preliminary study with high risk PPD women measured serum C-reactive 
protein and IL-6, as well as tryptophan, kynurenine, and the kynurenine/tryptophan ratio. C-
reactive protein levels were found to be positively related to atypical and total depression scores 
in the prepartum period and with atypical depression scores in the early postpartum period, while 
tryptophan was found to be negatively associated with total depression scores (Scrandis et al., 
2008). 
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For a summary of the reviewed studied observing changes in immunological pathways in 
perinatal depression see Table 3. 
 
6. Endocrinological studies 
Maternal hypothalamic-pituitary-adrenal (HPA) axis becomes gradually less responsive 
to stress as pregnancy progresses, being pregnancy a transient, physiologic, period of 
hypercortisolism (Mastorakos and Ilias, 2003). Alteration of HPA axis is considered as a robust 
biomarker of anxiety and depression: mid-pregnancy depression has been significantly 
associated with increased cortisol (O'Connor et al., 2014). In a prospective study by Glynn and 
Sandman (2014) depressive symptoms at 3-month postpartum were associated with elevated 
midgestational placental CRH (pCRH), whereas pCRH was not predictive of PPD symptoms at 
6-month postpartum, and prepartum cortisol/corticotrophin levels did not increase the risk of 
developing PPD. Meltzer-Brody et al. (2011) failed to find an association between midpregnancy 
pCRH levels and risk of PPD; similar data were reported by Zaconeta et al. (2015) measuring 
CRH levels in cerebrospinal fluid (CSF).  
A prospective study evaluated maternal self-report psychosocial distress at mid- and late 
gestation: cortisol levels were found to be directly correlate with maternal depression, anxiety 
and stress (Parcells, 2010). Maternal psychological well-being, parity status and birth weight 
were studied in relation to cortisol diurnal rhythm in pregnant women group: severe trait anxiety 
was associated with a flatter afternoon decline of cortisol (Kivlighan et al., 2008). A recent 
population-based longitudinal study of psychological wellbeing during pregnancy and the 
postpartum period assessed the association between evening salivary cortisol levels and 
depressive symptoms in the peripartum period. Women with postpartum EPDS score ≥ 10 had 
higher salivary evening cortisol at six weeks postpartum compared to healthy controls. 
Additionally, women with postpartum depressive symptoms had higher postpartum cortisol 
levels compared to both women with depressive symptoms antenatally and controls (Iliadis et al., 
2015). Salivary cortisol and chromogranin A/protein concentration changes were studied as 
stress markers during pregnancy: the elevation of cortisol and chromogranin A/protein in the 
saliva was found to be suppressed in the chronic high stress group during pregnancy (Tsubouchi 
et al., 2011). A recent study reported than women with depressive symptoms in late pregnancy 
had elevated awakening salivary alpha-amylase (sAA) levels compared with non-depressed 
controls, highlighting that symptoms of depression during late pregnancy are associated with 
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increased maternal sympathetic nervous system (SNS) activity (Braithwaite et al., 2015) A 
previous follow-up study reported higher ACTH levels in patients with postpartum thoughts of 
harming the infant, while no variations were found in CRH/cortisol levels (Labad et al., 2011). 
A longitudinal study assessed salivary cortisol awakening response (CAR) at the 36th 
week of gestation and 6 weeks postpartum in order to analyse the association of maternal HPA 
activity during pregnancy with maternal HPA responsiveness to stress after parturition. CAR in 
late pregnancy negatively predicted maternal ACTH, plasma cortisol and salivary cortisol, but 
not emotional stress reactivity at 8 weeks postpartum, whereas CAR at 6 weeks postpartum 
failed to predict ACTH, plasma cortisol, salivary cortisol or emotional stress responses at 8 
weeks postpartum (Meinlschmidt et al., 2010). 
Yim et al. (2010), found that women developing PPD symptoms had higher beta-
endorphin levels throughout pregnancy than healthy pregnant women.  
A prospective study found no associations between progesterone levels and mood 
symptoms in postpartum, whereas lower levels of evening cortisol in the immediate peripartum 
period were associated with PPD (Harris et al., 1996). Bloch et al. (2000) provided direct 
evidence in support of the involvement of the reproductive hormones estrogen and progesterone 
in the development of PPD, being women with a history of PPD more sensitive to mood-
destabilizing effects of gonadal steroids. In contrast, some years later, data by Klier et al. (2007) 
did not support the hypotheses of a role of sex hormones in the etiology of PPD. An Italian study 
evaluated serum allopregnanolone, progesterone, cortisol, prolactin, and estradiol in blood 
samples of primiparous women: serum allopregnanolone levels were significantly lower in 
women experiencing postpartum "blues" with respect to euthymic women, whereas progesterone 
levels were not significantly different (Nappi et al, 2001). Serum estradiol, progesterone and 
testosterone concentrations were measured upon admission for delivery and daily until the fourth 
postpartum day, without finding an association between the occurrence of postpartum mood 
disorders and sex steroid hormone levels, whereas preterm labour may be associated with a 
higher risk of postpartum mood disturbances (Chatzicharalampous et al.,  2011).  
A prospective observational study evaluated whether the presence of thyroperoxidase 
antibodies (TPOAbs) during pregnancy can be regarded as a marker for depression in the first 
year postpartum: it reported a positive correlation between TPOAbs presence during early 
pregnancy and the development of PPD (Kuijpens et al., 2001). A previous pilot study measured 
thyroid and adrenal hormones and mood symptoms at the end of pregnancy and postpartum in 12 
women with major depression history and 14 women with negative psychiatric history. Subjects 
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with prior depressions had significantly higher T3, T4, TSH and cortisol levels during the 
puerperium, while subjects with higher levels of postpartum dysphoria had lower T4 and free T4 
levels as well as higher T3 uptake at 38 weeks of pregnancy, higher cortisol levels during the 
puerperium (Pedersen et al., 1993). 
Oxytocin (OT) system contribute to parental, romantic and filial attachment in humans. 
Skrundz et al. (2011) measured plasma OXT in a prospective study during pregnancy reporting 
that OXT concentration in mid-pregnancy significantly predicted PPD symptoms at 2 weeks 
postpartum.  
 For a summary of the reviewed studied observing changes in endocrinological 
pathways in perinatal depression see Table 4. 
 
7. Conclusions 
In 1998 The National Institutes of Health Biomarkers Definitions Working Group defined 
a biomarker as "a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, that has to be reproducible and objective in indicating a medical 
state observed and has to repeatedly show to correctly predict clinical outcomes (Strimbu et al., 
2010). In the last decades, several biomarkers have been investigated in relation to PPD, but only 
some of them have being associated with increased risk of depressive symptoms during 
pregnancy and postpartum. With regard to biochemical studies, maternal iron status was not 
associated with PPD onset while biopterin, homocysteine, zinc, vitamin B12 levels have been 
reported to have a positive association with PPD onset although in single studies having small 
sample size, thus needing replications. It is interesting to underline that five non-controlled 
studies with a total number of more than 5,000 women, found a relation between vitamin D 
levels during pregnancy and risk of future PPD. From these studies it seems that vitamin D levels 
could be a possible useful biomarker for PPD early detection, being low vitamin D levels in 
pregnancy associated to higher EPDS scores (Murphy et al., 2010; Cassidy et al., 2012a; 
Brandenbarg et al., 2012; Robinson et al., 2014; Gur et al., 2014; Accortt et al., 2015; Miyake et 
al., 2015a). BDNF serum levels may predict the development of mood disorders in the perinatal 
period (Pinheiro et al., 2010; Fung et al., 2015). Cochrane reviews (Miller et al., 2013; Dennis 
and Dowswell, 2013) conclude that there is insufficient evidence to state that selenium, DHA or 
EPA supplementation prevent PPD: most studies have been judged to be of low-to-moderate 
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quality for small sample sizes and failure to adhere to Consolidated Standards of Reporting 
Trials guidelines (Larqué et al., 2012). However a recent review by Shapiro et al. (2012) seems 
to partially support a link between n-3 PUFAs, the 5-HTT genotype, and PPD. 
In line with previous studies reporting higher antibody levels against viruses in pregnant 
mothers of patients with psychotic disorders, a very recent case- control study investigated the 
potential association between viral infections during pregnancy and progeny with psychotic 
disorders, finding a significantly lower viral prevalence in the pregnant mothers of offspring with 
schizophrenia, thus confirming that a more prominent maternal immune activity during 
pregnancy can be considered a risk factor for future psychotic disorders (Canuti et al., 2015). As 
gestation progresses, placenta becomes increasingly resilient to maternal inflammation, but there 
is a narrow window in gestation when the placenta is still vulnerable to immune challenge, with 
implications on early cortical neurogenesis in foetal brain (Burton and Fowden, 2015).  
With regard to immunological and endocrinological studies, regulatory T cell count 
seems to predict PPD (Krause et al., 2014), having women with a history of depression an 
amplified sensitized inflammatory response (Azar and Mercer, 2013; Scrandis et al., 2008). Most 
studies found an association between cytokines and PPD (see below) while only two small 
studies have found no association (Cheng et al., 2014; Kianbakht et al., 2013).  
Abnormal HPA axis function is frequently found in pregnant women affected by MDD, 
who have high levels of cortisol that can pass through the placenta, determing preterm labor and 
reducing birth weight. Most studies measuring cortisol levels in relation to PPD found an 
association however some did not (Kivlinghan et al., 2008; Meinlschmidt et al., 2010; Meltzer-
Brody et al., 2011; Zaconeta et al., 2015). Endocrinological studies show that TPOAbs presence 
during gestation is associated with the occurrence of subsequent depression during the 
postpartum period but further studies are necessary to draw sound conclusions (Kuijpens et al., 
2001). Women with PPD seem to display an increased sensitivity to estrogen signaling, 
confirming the previously proposed hypothesis of increased sex-steroid sensitivity as a 
susceptibility factor for PPD (Mehta et al., 2014; Guintivano et al., 2014). In line with such data 
a recent review postulated that reproductive hormones may influence every biological system 
especially in a subgroup of women constituting a "hormone-sensitive" PPD phenotype, as 
estrogen are closely tied to HPA axis and inflammation, all these factors may contribute to the 
etiology of PPD (Schiller et al., 2015).  
Regarding genetic studies a recent systematic review by Figueiredo and colleagues 
(2014) summarize available data on PPD, reinforcing the idea of a pathophysiological role of the 
hormonal changes. Without cytokine glucocorticoid feedback, a pregnant woman's ability to 
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regulate inflammation is limited, potentially contributing to adverse maternal and infant 
outcomes. In particular, IL-6 seems to be a reliable and useful biomarker of risk in perinatal 
depression as confirmed in different studies (Boufidou et al., 2009; Christian et al., 2009, 2010; 
Krause et al., 2014; Cassidy-Bushrow et al., 2012b; Azar et al., 2013). PPD magnetic resonance 
studies are limited in number and design, a recent systematic literature search yielded only 
eleven studies in which findings appear to replicate those obtained in MDD (Fiorelli et al., 
2015). As for other mental disorders, we have to take into account that PPD is a complex 
disorder involving gene-environment interactions (GEI). Moreover it is important to underline 
that some of the cited biomarkers, possibly predictive of PPD onset, have been previously linked 
to MDD (e.g vitamin D, IL-6, PUFA), supporting a common etiopathogenetic pathways. Future 
studies should focus on specific PPD biomarkers that could represent an early marker of disease, 
thus modifying PPD natural course. Prospective and controlled studies are needed to better 
explore for example the supplementation with micronutrients that, in the last years, have shown a 
role in the synthesis and absorption of neurotransmitters and in epigenetic modifications. 
Affective disorders in pregnant women have to be detected as soon as possible and 
treated with focused therapies in order to prevent deleterious effects and promote the welfare of 
both mother and baby. Although it was not in the aim of this review we have to underline how a 
woman’s good mental health status can contribute to the infant’s future well being, as some 
studies have shown. More longitudinal and interventional studies, are needed to increase our 
knowledge about etiology, development and management of maternal distress, being a priority 
the search for reliable biomarkers for at-risk mothers in the next future. 
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Figueira et al., 2010 
 
227 mothers 
EPDS, biological, psychiatric and 
environmental assessment and 
PPD risk. 
 
No difference in BDNF genotype 
distribution between depressed/non-
depressed women. No association 
between BDNF polymorphisms and 
PPD. 






Genes encoding for BDNF, 
serotonin transporter (5-HTT) and 
Period2 (PER2). 
EPDS, stressful life events (SLEs) 
and maternity stressors assessment  
Significant association between BDNF 
Met66 carrier status and development 
of PPD symptoms. A cumulative effect 
was detected with carriers of a greater 
number of 5-HTTLPR S and 
BDNFVal66Met Met alleles reporting 
higher EPDS scores, if delivered 
during autumn/winter.  





Blood mononuclear cells A distinctive gene expression signature 
was observed after delivery among 
mothers with an emergent PPD. 
Xie et al., 2009 
 
69 pregnant women  
 
Pilot study 
Genotyping rs174553, rs99780, 
rs174575, and rs174583 in 
FADS1/FADS2, blood lipid fatty 
acids and EPDS. 
 
Association between rs174575 and 
PPD risk. SNPs in FADS1/FADS2 are 
associated with higher blood lipid LA 
and lower ARA and PPD risk. 
Mehta et al., 2014 
 
62 women  
Gene expression and plasma 
estradiol and estriol measure. 
Women with PPD displayed an 
increased sensitivity to estrogen 
signalling. 





SCID, MINI, EPDS, MADRS. 
Genomic DNA extraction for nine 
ESR1 variants and detection of a 
significant association with EPDS 
scores.  
Role for ESR1 in the etiology of PPD, 
possibly through the modulation of 
serotonin signalling. 
El-Ibiary et al., 2008 
case-control, 
prospective study 
Steroid hormone function, 
neurotransmitter function and 
neurotrophin function (BDNF) 
Association of three single nucleotide 
polymorphisms in the serotonin 2A 
receptor (HTR2A) with PPD 
Bell et al., 2015 
 
545 pregnant women  
 
case-control study 
OXTR DNA methylation (CpG 
site -934) and genotype (rs53576 
and rs2254298). 
Evidence of an interaction between 
rs53576 and methylation in the OXTR 
gene amongst women who did not 
have depression prenatally but 
developed PPD. GG genotype showed 
2.63 greater odds of PPD for every 
10% increase in methylation level. 




Schedule for Affective Disorders 
and Schizophrenia (CM-SADS)— 
Six single nucleotide 
polymorphisms were selected 
The TPH2 2755A allele was found 
only in women with peripartum major 
depression and anxiety disorder and 
exhibited a dominant gene action with 
 35 
women (117 major 
depression and/or 
anxiety disorder; 83 
healthy controls) 
from previously profiled genetic 
information of TPH2. 
an estimated disease risk of 1.73. 
 




Depression assessment EPDS. 
Genotype of the 5-HTTLPR 
assessment. 
 
The 5-HTTLPR S-allele carrier status 
predicted late postpartum depressive 
symptom severity only in the presence 
of negative life events.  
Binder et al., 2010 
 
274 women with a 




Assessment (SCID), HAM-D  
5-HTTLPR genotyping and  
evaluation  
5-HTTLPR S-allele carrier status 
predicted the occurrence of a MDE in 
the early post-partum period only.  
Doornbos et al. 
2009a 
 
89 pregnant women 
Depressive symptoms assessment 
EPDS.  
MAOA, COMT and 5-HTT 
polymorphisms were analyzed 
A significant interaction between the 
development of depressive symptoms 
and polymorphisms in 5-HTT; MAOA 
and COMT and MAOA x COMT. 
Women carrying the combination of 
low activity variants of MAOA and 








Genotyping of single nucleotide 
polymorphisms (SNPs) in TPH2 
and SNPs. 
 
Significant associations between the 
haplotype block in the promoter region 
of TPH2 and depression. Influence of 
a haplotype block in intron 8 on 
depression scores during pregnancy. 
Zhang et al. 2014 
 
192 women with 
MDD 
BDI, HAMA, HRSD, SAS, PSQI, 
and EPDS, PHQ-9.  
SLC6A4 promoter VNTR 
polymorphism genotyping. 
5-HTTLPR is strongly associated with  
MDD in postpartum women. Women 
who carry the long allele when 
experiencing maternal pregnancy 
complications showed higher 
prevalence ratios for symptoms of 
postpartum depression.  
Engineer, 2013 
 






Genotyping of the BclI and 
ER22/23EK single nucleotide 
polymorphisms (SNPs) of the GR 
and the haplotype-tagged 
rs1876828, rs242939 and 
rs242941 SNPs of the CRHR1.  
Evidence that specific SNPs of genes 
involved in 'stress' responses might 
contribute in the genetics of high-risk 
for depression during pregnancy and 
postpartum. 
 
Alvim-Soares et al., 
2013 
116 women 
COMT Val158Met SNP was 
evaluated, EPDS collected 
An association was found between the 
COMT AA genotype (Met/Met) and 
PPD 






DNA methylation profiles  cross-
referenced with syntenic locations, 
which demonstrated murine 
hippocampal DNA methylation 
changes in response to long-term 
treatment with 17b-estradiol. 
Decrease in the ratio of monocytes to 
lymphocytes and granulocytes in the 
antenatally depressed women that 





Gene expression from peripheral 
blood mononuclear cells 
Downregulation of transcription after 
delivery, with differential immune 
activation, decreased transcriptional 
engagement in cell proliferation, and 
DNA replication and repair processes 
Osborne et al., 2015 
 
 
TTC9B and HP1BP3 DNA 
methylation association to the 
change in estradiol and 
allopregnanolone over the course 
of pregnancy 
Epigenetic variation at these loci may 
be important for mediating hormonal 










































A complete blood count, ZPP (zinc 
protoporphyrin), serum ferritin, and 
sTfR (soluble transferrin receptor) 
assessment. 
EPDS.   
No relations between maternal iron 
status and maternal symptoms of PPD. 
 
Omura et al., 2002 
 
14 normal 
pregnant and 15 
normal puerperal 
women 
Plasma total biopterin and 
tetrahydrobiopterin levels measure. 
Plasma biopterin levels in pregnancy 
and the early puerperal period closely 
resembled those of patients with mood 
disorders who show depressive 
symptoms. 
Huang et al., 2015 
43 women 
Homocysteine level.  Homocysteine levels in women with 
PPD was significantly higher than that 
in the control group. 





Depressive symptoms and serum zinc 
and magnesium level in antepartum 
and postpartum women.  
BDI. 
Relationship between severity of 
depressive symptoms and decreased 
serum zinc (but not magnesium) 
concentration in postpartum 
depression. 








Kessler Psychological Distress Scale 
(K-10). 
Nutritional, clinical and biochemical 
factors assessment. 
No association between blood 
concentrations of vitamin B12, folate 
and depressive symptoms. 








Serum 25(OH)D samples collection 
and EPDS. 
Negative correlation between vitamin 
D levels and PPD, being women with 
lower vitamin D levels at higher risk 
of depression. 
Cassidy-Bushrow 
et al., 2012a 
 
178 women 
Vitamin D dosage and depression 
symptoms measure with CES-D. 
Increased depressive symptoms in 
African American women with lower 





Maternal serum vitamin D.  
CES-D  
Women with high levels of depressive 
symptoms (28%) had lower vitamin D 
concentrations than women with low 
levels of depressive symptoms. 
Robinson et al., 
2014 
Serum collection of 25(OH)-vitamin 
D. 
Women in the lowest quartile for 





likely to report a higher level of PPD 
symptoms than women who were in 
the highest quartile for vitamin D.  




Serum 25(OH)D3 levels  
Maternal PPD assessment with 
EPDS. 
Significant relationship between low 
25(OH)D3 levels in mid-pregnancy 
and high EPDS scores. Negative 
correlation between vitamin D levels 
and EDPS. 
Accortt et al., 
2015 
91 women  
Prospective study 
Vitamin D status (serum 25-
hydroxyvitamin D, 25[OH]D, 
inflammatory markers dosage 
An inverse association between 
prenatal log 25(OH) D and PPD 
symptomatology approached 
significance, IL-6 and IL-6/IL-10 ratio 
significantly moderated the effect. 
Among women with higher levels of 
inflammatory markers, lower prenatal 
log 25(OH)D was associated with 
significantly higher PPD symptoms.  









Dietary intake assessment during the 
preceding month using a self-administered 
diet history questionnaire.  
Significant association between higher 
dietary vitamin D intake and a lower 
prevalence of depressive symptoms 
during pregnancy, independent of 
potential dietary and nondietary 
confounding factors.  
Otto et al., 2003 
 
112 women 
DHA and its status indicator n-6 
docosapentaenoic acid (n-6DPA, 
22:5n-6) in the plasma phospholipids. 
EPDS. 
The postpartum increase of the 
functional DHA status, expressed as 
the ratio DHA/n-6DPA, was 
significantly lower in the 'possibly 
depressed' group compared to the non-






cohort study  
EPDS Assessment. 
Serum concentrations of triglycerides, 
total cholesterol, and low- and high-
density lipoproteins were the main 
exposures.  
Lower EPDS scores in women 
classified in the 3rd tertile of the 
distribution of HDL-c concentrations 
during pregnancy, when compared to 
those classified in the first or second 
tertile. Inverse association between 







EPA-rich fish oil, DHA-rich fish oil, 
or soy oil placebo random intake. 
BDI and MINI  
 
No differences between groups in BDI 
scores. Significant increase of post 
supplementation concentrations of 
serum EPA and serum DHA 
respectively in EPA- and DHA-rich 
fish oil groups. Inverse association 
between serum DHA-concentrations at 
34-36 weeks and BDI scores in late 
pregnancy. 
Shiraishi M., 2015 
 
329 pregnant 
EPDS, plasma EPA and DHA 
concentrations assayed.  
Significant association between lower 
plasma docosahexaenoic acid 














Cortisol response to a controlled 
stressor, the TSST was measured 
from saliva samples collected upon 
arrival to the laboratory and after the 
completion of the TSST. 
 
Women in the DHA supplementation 
had lower cortisol output and a more 
modulated response to the stressor. 
 




EPDS assessment  
Blood collection to generate data on nine 
PUFA variables. 
 
Univariate associations between pre-
natal depression and measures of 
blood fatty acids. Such associations 
were not found post-natally, but 
different associations were quantified 
between EPDS-diagnosed depression 










Fatty acid status  
Screening for PPD using the EPDS. 
Association between a low omega-3 
index in late pregnancy and higher 
depression score three months 
postpartum. Inverse correlation 
between DPA content, DHA content, 
omega-3 index, omega-3/omega-6 
ratio, total HUFA score, omega-3 
HUFA score with the EPDS score. 
Sallis, 2014 Association between levels of two 
omega-3 FAs (DHA and EPA) and 
perinatal onset depression, antenatal 
depression and postnatal depression. 
A weak positive association was found 
with FAs and PPD. 
Vaz, 2014 
 
234 pregnant women  
prospective cohort 
study 
Suicide risk and MDE defined according to 
the MINI. Fatty acid compositions 
determined  
Higher likelihood of suicide risk among 
women with higher AA levels and adrenic 
acid levels. Higher likelihood of MDE among 





Plasma LC-PUFAs measure.  
STAY and EPDS assessment. 
Lower plasma total omega-3 PUFA 
concentrations and higher plasma 
omega-6: omega-3 PUFA ratios, were 
associated with increased antenatal 
anxiety, but not postpartum anxiety.  





Women were supplemented daily 
with placebo, DHA (220 mg) or 
DHA+AA (220 mg each). Fatty acid 
analyses. 
EPDS 
The supplementation groups did not 
differ in mean EPDS scores or 
changes in EPDS scores, nor in 
incidence or severity of postpartum 
blues. Red blood cell DHA, AA and 
DHA/AA ratio did not correlate with 
EPDS or blues scores.  
Lommatzch, 2006, 
 
40 pregnant and 
EPDS assessment  
Blood collection, measure BDNF 
serum concentrations, 5-HT and 
Maternal serum levels BDNF were 
markedly decreased, both before and 
after childbirth. BDNF correlated with 
 40 
40 non pregnant 
women 
 
Transforming growth factor b1 (TGF-
b1) 
decreased 5-HT levels in serum. There 
were significantly higher cortisol 
levels in cases of maternal depression 










PHQ-9 assessment.  
Maternal serum BDNF levels were measure. 
 
 
Maternal early pregnancy serum BDNF levels 
were significantly lower in women with 
antepartum depression compared to women 
without depression. Lower BDNF levels were 
associated with increased odds of maternal 
antepartum depression. Women whose serum 
BDNF levels were in the lowest three 
quartiles had 1.61-fold increased odds of 
antepartum depression as compared with 
women whose BDNF levels were in the 






Maternal serum BDNF levels  
Significantly lower maternal early 
pregnancy serum BDNF levels in 
women with antepartum depression 
compared to women without 
depression. 









Dietary intake assessment during the 
preceding month using a self-administered 
diet history questionnaire. 
Higher intake of yogurt and calcium 
may be associated with a lower 
prevalence of depressive symptoms 
during pregnancy 






(MTHFR) C677T genotype on 
change in depression scores, and 
carried out our analysis of folic acid 
supplementation and depression 
stratifying by genotype. 
No strong evidence that folic acid 
supplementation reduces the risk 
of depression during pregnancy and up 
to 8 months after pregnancy. Low 
folate as a risk factor for depression 
outside of pregnancy, especially 
among women with the MTHFR 






HRSD; fatty acids, plasma folate was 
measured, maternal plasma ascorbic 
acid concentrations were determined. 
No association between Essential 
Fatty Acid or Micronutrient patterns 







Measure of plasma folate and vitamin B12.  
EPDS assessment. 
Plasma folate concentrations 
significantly lower in women with 
probable antenatal depression than 
those without. No difference in folate 
concentrations in women with and 





















Serum C-reactive protein and IL-6, 
tryptophan, kynurenine, and the 
kynurenine/tryptophan ratio.  
C-reactive protein levels were found to be 
positively related to atypical and total 
depression scores in the prepartum period 
and with atypical depression scores in the 
early postpartum period. Negative 






A blood sample and a CSF sample 
TNF-a and IL-6 were quantified with 
an ELISA assay, EPDS 
Cytokine levels were positively associated 
with depressive mood during the first four 







PSS and CES-D. 
Measure of serum levels of IL-6 and 
TNF-alpha. 
Higher scores on the CES-D were related 
to significantly higher levels of IL-6 and 
marginally higher TNF-alpha. Perceived 
stress was not significantly related to 
serum levels of IL-6 or TNF-alpha.  







Immune parameters (neopterin, 
regulatory T cells, CXCR1, CCR2, 
MNP1 and CD11a)  
MADRS, EPDS 
Regulatory T cells were significantly 
increased prenatal and postnatal in mothers 
with postnatal depressive symptoms.  
Mothers with postnatal depressive 
symptoms showed already prenatal 
significantly elevated neopterin levels.  




women   
Set of questionnaire and a 1 ml of 
blood at both data collection point 
All cytokines analysed except for G-CSF, 
an anti-inflammatory cytokine that 
increased, did not showed significant 
change from late pregnancy to postpartum. 
Kianbakht et 
al., 2013 
Peripheral venous blood from 
depressed women and cord venous 
blood from their neonates. 
Evaluation serum levels of 
immunoglobulins IgG, IgM and IgA 
and complements C3 and C4 were 
determined. 
Immune parameters of depressed women 
were not significantly different from 
controls. Lymphocyte counts in neonates 
of women with major and minor 
depression were increased, whereas ratio 
of the cord blood level of IgG to the 
maternal blood level of IgG in neonates of 
women with major depression were 






CES-D scale and inflammatory 
biomarkers (high-sensitivity C-
reactive protein [hs-CRP], IL-6, IL-
10, IL-1β, and TNF-α 
Depressive symptoms are associated with 
increased inflammation among pregnant 
African-American women 
















CES-D; cytokine blood collection, 
serum levels of macrophage 
migration inhibitory factor (MIF) 
were assayed 
Depressive symptoms predicted 
exaggerated MIF production following 







Measure of plasma pro- and anti-
inflammatory cytokines.  
EPDS assessment. 
Cortisol AUC was higher in symptomatic women 
on Day 14. Family history of depression, day 14 
cortisol AUC, and the day 14 IL8/IL10 ratio were 


























Tab. 4 Endocrinological studies 
 
Author, year Sample 
size 
Methods Results 
Pedersen et al., 1993 
 
12 pregnant women 
with major 
depression history 





Measure of thyroid, adrenal 
hormones and mood 
Subjects with prior depressions had 
significantly higher T3, T4, TSH and 
cortisol levels during the puerperium. 
Lower T4 and free T4 levels as well as 
higher T3 uptake at 38 weeks of 
pregnancy, higher cortisol levels 
during the puerperium in subjects with 
higher levels of postpartum dysphoria. 
Kuijpens, 2001  
 





TSH, free thyroxine and TPOAb 
testing, depression assessment 
according to the Research 
Diagnostic Criteria (RDC). 
 
After the exclusion of women who 
were depressed at 12 weeks gestation, 
the presence of TPOAbs during early 
pregnancy was still found to be 
associated with the development of 
PPD; after exclusion of women who 
had had depression in earlier life, 
TPOAb during early gestation was still 




agonist leuprolide acetate, adding 
back supraphysiologic doses of 
estradiol and progesterone for 8 
weeks, and then withdrawing both 
steroids under double-blind 
conditions. 
Five of the eight women with a history 
of PPD (62.5%) and none of the eight 
women in the comparison group 
developed significant mood symptoms 
during the withdrawal period. Increase 
in depressive symptoms in women 
with a history of PPD. 






Significant risk factors for early 
postpartum depressive symptoms were 
a history of mental illness including 
past PPD, premenstrual dysphoric 
disorder, and mood symptoms during 
the third trimester. 






progesterone, cortisol, prolactin, 
and estradiol.  
HAM-D 
Serum allopregnanolone levels were 
significantly lower in those women 
experiencing postpartum "blues" with 
respect to euthymic women; 
progesterone levels did not differ 
significantly.  
Klier et al., 2007 
 
192 pregnant women 
EPDS 
Levels of estrogen and 
progesterone. 
Results in contrast to the current 
hypotheses of estrogen withdrawal or 
hypogonadal levels as an etiological 
factor for PPD.  
Pařízek, 2014 
 
Samples of maternal blood, mixed 
umbilical cord blood collection. 
Changes in androgens levels 
correlating with postpartum mood 
 44 
44 pregnant women HAM-D. 
 
disorders. After childbirth both 
testosterone, most likely of maternal 
origin and estrogens from the fetal 






reprogramming events, DNA 
methylation profiles and risk PPD 
PPD risk correlated significantly with 
17β-estradiol (E2) induced DNA 
methylation change. 
Chatzicharalampous 
et al., 2011 
 
57 post partum 
women 
PBQ and EPDS.  
Measure of serum estradiol, 
progesterone and testosterone 
concentrations upon admission for 
delivery and daily until the fourth 
postpartum day.. 
No association between the occurrence 
of postpartum mood disorders and sex 
steroid hormone levels. Preterm labour 
may be associated with a higher risk of 







Saliva collection for 
characterisation of cortisol and 
progesterone profiles. 
Association between lower levels of 
evening cortisol in the immediate 




98 low-risk pregnant 
women (51 
primiparae) 
Saliva collection cortisol Assay. 
STA-Y; PSS 
Regulation of the HPA axis may differ 
by parity status with downstream 
implications for fetal growth and 
development. Higher trait anxiety was 
associated with a flatter afternoon 
decline for all mothers.  
Meinlschmidt et al., 
2010 
 





Assessment of the salivary cortisol 
awakening response (CAR) to a 
psychosocial laboratory stressor  
CAR in late pregnancy negatively 
predicted maternal ACTH, plasma 
cortisol and salivary cortisol, but not 
emotional stress reactivity at 8 weeks 
postpartum. CAR at 6 weeks 
postpartum failed to predict ACTH, 
plasma cortisol, salivary cortisol or 
emotional stress responses at 8 weeks 
postpartum. 







The relationship between pCRH  
Maternal depression assessed  
CES-D and EPDS 
 
No association between higher 
midpregnancy pCRH and an increased 
risk of PPD 
Tsubouchi, 2011 
 
69 pregnant women 
Salivary cortisol levels and 
chromogranin A/protein  
Zung self-rating depression scale 
and GHQ-28. 
Cortisol levels in the saliva of pregnant 
women showed biphasic change 
during pregnancy. Chromogranin 
A/protein levels in the saliva of 
pregnant women increased in the 
second and the early third trimesters 
and decreased to the puerperal period. 
Salivary cortisol concentrations of the 
chronic high stress group were 
 45 
significantly lower compared with 
those of the normal group. Salivary 
chromogranin A/protein 
concentrations of the chronic high 
stress group were also significantly 
lower than those of the normal group. 
Labad et al., 2011 
 
132 post partum 
women 
Assessment for trait anxiety, 
social support, peripartum or 
postpartum anxiety or depression, 
stressful life events and obstetric 
variables, Postpartum thoughts of 
harming the infant. 
Measure of serum cortisol, and 
plasma CRH and ACTH levels. 
Higher ACTH levels in women with 
postpartum thoughts of harming the 
infant. No significant differences in 
CRH or cortisol levels. 
 
Katz, 2012 
   
106 pregnant women 
with a lifetime 
history of mood or 
anxiety disorders    
 
Maternal RNA from whole blood, 
plasma and the BDI were 
collected.  
The expression of 16 genes in 
whole blood involved in 
glucorticoid receptor (GR). 
Plasma concentrations of 
progesterone, estradiol and 
cortisol were measured. 
mRNA expression of a number of GR-
complex regulating genes was up-
regulated over pregnancy. Women 
with depressive symptoms showed 
significantly smaller increases in 
mRNA expression of four of these 
genes - FKBP5, BAG1, NCOA1 and 
PPID. GR sensitivity diminished with 
progression of pregnancy and 
increasing maternal depressive 
symptoms. Plasma concentrations of 
gonadal steroids and cortisol did not 
differ over pregnancy between women 




170 pregnant women 
 
Blood samples were obtained and 
assayed to determine maternal 
cortisol, adrenocorticotropic 
hormone, and pCRH 
concentrations.  
Depressive symptoms at 3 months 
postpartum were associated with 
elevated midgestational pCRH and 
also accelerated trajectories of pCRH. 
Placental CRH was not predictive of 
PPD symptoms at 6 months 
postpartum. Prepartum cortisol and 
corticotrophin profiles were not 
associated with PPD symptoms. 
O’Connor, 2014 
 
101 women at mid-
pregnancy and early 
third trimester. 
Links between diurnal cortisol and 
mood symptoms from self-report 
questionnaire and diagnostic 
interview. 
There were modest but significant 
associations between depression and 
elevated cortisol, indexed by a 
decreased morning level and 
diminished diurnal decline. 
Reynolds, 2015 
 







term placental mRNAs of 11beta-
hydroxysteroid dehydrogenase 
type 2 (HSD2B11), type 1 
(HSD1B11), glucocorticoid 
(NR3C1), mineralocorticoid 
receptors (NR3C2) and serotonin 
transporter (SLC6A4).  
Higher placental NR3C1 mRNA partly 
mediated the association between 
maternal depressive symptoms during 





59 pregnant women 
Maternal depression, anxiety and 
stress assessment and an estimate 
of the stress hormone cortisol 
from maternal saliva samples. 
High incidences of prenatal 
depression, anxiety and stress across 
the 3rd trimester. 
 
Braithwaite et al., 
2015 
 
76 pregnant women 
EPDS. 
Saliva samples, to be assayed for 
alpha-amylase activity. 
Women with depressive symptoms in 
later pregnancy had elevated 
awakening sAA levels compared with 
non-depressed controls, and continued 
to have raised sAA throughout the day.  
Iliadis et al., 2015 
 





Evening salivary samples for 
cortisol analysis.  
Higher salivary evening cortisol in 
women with postpartum EPDS score ≥ 
10 compared to healthy controls. 
 
Zaconeta et al., 2015 
 
107 healthy pregnant 
women  
22 nonpregnant 
healthy women  
prospective cohort 
study 
CRH in CSF was measured in 
pregnant and nonpregnant women  
The association between CSF 
CRH concentration  
EPDS. 
CRH concentration in the CSF was 
significantly higher in pregnant than in 
nonpregnant women. No difference in 
CRH concentration between women 
without depressive symptoms and 
women showing such symptoms 





100 pregnant women 
Blood samples for the OXT 
assessment.  
EPDS. 
An increased occurrence of depressive 
symptoms in the first 2 weeks after 
delivery in individuals with low 
plasma OXT concentrations in 
pregnancy, also after controlling for 
prepartal EPDS scores. 
Yim, 2010 
 
307 pregnant women 
Blood samples pre and  
postpartum for assessment of beta-
endorphin.  
CES-D and the EPDS. 
Women developping PPD symptoms 
had higher levels of beta-endorphin 
throughout pregnancy compared to 
women without PPD symptoms.  
 
 
